Pneumonia News and Research

Latest Pneumonia News and Research

Two-step regimen of experimental MERS vaccines show promise in mice

A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines. Vaccinated mice produced broadly neutralizing antibodies against multiple strains of the MERS coronavirus (MERS-CoV), while vaccinated macaques were protected from severe lung damage when later exposed to MERS-CoV.

29 Jul 2015

Less invasive endovascular aortic repair benefits most patients, provides quick recovery

Each year, nearly 40,000 Americans undergo elective surgery to repair an abdominal aortic aneurysm with the goal of preventing a life-threatening rupture of this potentially dangerous cardiovascular condition.

24 Jul 2015

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Kyprolis (carfilzomib) for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy.

23 Jul 2015

Southampton scientists set to analyse investments into infectious disease research

Scientists at the University of Southampton are set to analyse research investments into infectious disease research, particularly pneumonia and maternal and neonatal infections, after receiving over £370,000 in funding from the Bill & Melinda Gates Foundation.

23 Jul 2015

Retail meat harbors disease-causing Klebsiella pneumoniae, shows new study

Chicken, turkey and pork sold in grocery stores harbors disease-causing bacteria known as Klebsiella pneumoniae, according to a new study. The research, which was published online today in the journal Clinical Infectious Diseases, shows that contaminated meat may be an important source of human exposure to Klebsiella.

23 Jul 2015

C2N-8E12 (ABBV-8E12) gets orphan drug designation from FDA for PSP treatment

C2N Diagnostics and AbbVie today announced that the U.S. Food and Drug Administration has granted their investigational recombinant humanized anti-tau antibody, C2N-8E12 (ABBV-8E12), an orphan drug designation for the treatment of progressive supranuclear palsy (PSP).

17 Jul 2015

UK investment lacking for pneumonia research

UK investment in pneumonia research is lacking when compared to spending on influenza and tuberculosis, according to a new study by the University of Southampton and University College London.

15 Jul 2015

Scientists discover new variant of streptococcal bacteria that contributes to severe infections

Scientists have discovered a new variant of streptococcal bacteria that has contributed to a rise in disease cases in the UK over the last 17 years.

15 Jul 2015

New study highlights burden of community-acquired pneumonia hospitalizations among U.S. adults

Viruses, not bacteria, are the most commonly detected respiratory pathogens in U.S. adults hospitalized with pneumonia, according to a New England Journal of Medicine study released today and conducted by researchers at Centers for Disease Control and Prevention and hospitals in Chicago and Nashville, including Vanderbilt University Medical Center.

15 Jul 2015

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Today AbbVie announced the European Commission granted marketing authorization for IMBRUVICA (ibrutinib) as the first treatment option available in all 28 member states of the European Union for the treatment of Waldenstrom's macroglobulinemia (WM), a rare, slow growing blood cancer, in adult patients who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.

12 Jul 2015

Janssen-sponsored Phase 2b trial shows guselkumab effective in treating moderate to severe plaque psoriasis

Results published today in The New England Journal of Medicine from a Janssen Research & Development, LLC (Janssen)-sponsored Phase 2b trial showed up to 86 percent of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician's Global Assessment (PGA) score of cleared psoriasis or minimal psoriasis at week 16, the study's primary endpoint.

9 Jul 2015

Surgery delays for elderly patients with traumatic spinal cord injury

Older patients with traumatic spinal cord injury experience significant delays in being transferred to a specialist treatment centre and receiving surgery, compared with younger patients, study findings show.

8 Jul 2015

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains.

8 Jul 2015

Sepsis readmissions have significant impact on health care expenditures in California

The Affordable Care Act created several national initiatives aimed at reducing hospital readmission rates for heart attacks, congestive heart failure and other common high-risk conditions. But there is still no national program intended to address sepsis, a potentially life-threatening illness caused by infection.

8 Jul 2015

Older patients with traumatic spinal cord injury less likely to get surgical treatment compared with younger patients

Older patients with traumatic spinal cord injury are less likely than younger patients to receive surgical treatment and experience a significant lag between injury and surgery, according to new research in CMAJ (Canadian Medical Association Journal).

7 Jul 2015

Researchers awarded grant from British Council to reduce burden of infectious disease in Malaysia

A group of collaborators led by the University of Southampton have been awarded a British Council Newton Fund Institutional Links Grant to support ground-breaking research towards reducing the burden of infectious disease in Malaysia.

7 Jul 2015

UTHealth School of Public Health working to improve health of Hispanics living along Texas-Mexico border

Sylvia Hernando became a Community Health Worker (CHW) because she wanted to help others. Hernando had been a stay-at-home mother and was looking to go back to school when she heard about the CHW certification program at The University of Texas Health Science Center at Houston School of Public Health.

6 Jul 2015

Mortality rates vary depending on socioeconomic differences among areas in Europe

For a number of years now, scientific literature has questioned whether mortality rates depend on socioeconomic differences among the population. Recently, a new study carried out in 15 European cities - including Barcelona and Madrid - detected inequalities for the majority of causes, concluding that higher levels of poverty are associated with higher mortality rates and there is a great deal of variation among areas.

2 Jul 2015

Dr. Jian-Dong Li receives $1.6 million to develop novel therapeutic targets to treat middle-ear infections

Dr. Jian-Dong Li, a professor and director of the Institute for Biomedical Sciences at Georgia State University and a Georgia Research Alliance Eminent Scholar in Inflammation and Immunity, has received a five-year, $1.6 million federal grant to develop novel anti-inflammatory therapeutics against middle-ear infections.

2 Jul 2015

Aridis' Aerucin gets FDA Fast Track Designation for treatment of hospital-acquired and ventilator-associated pneumonia

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today that the U.S. Food and Drug Administration granted Fast Track Designation to its fully human monoclonal antibody Aerucin for the treatment of hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa.

30 Jun 2015

Pneumonia News and Research

Latest Pneumonia News and Research

Two-step regimen of experimental MERS vaccines show promise in mice

Less invasive endovascular aortic repair benefits most patients, provides quick recovery

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Southampton scientists set to analyse investments into infectious disease research

Retail meat harbors disease-causing Klebsiella pneumoniae, shows new study

C2N-8E12 (ABBV-8E12) gets orphan drug designation from FDA for PSP treatment

UK investment lacking for pneumonia research

Scientists discover new variant of streptococcal bacteria that contributes to severe infections

New study highlights burden of community-acquired pneumonia hospitalizations among U.S. adults

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Janssen-sponsored Phase 2b trial shows guselkumab effective in treating moderate to severe plaque psoriasis

Surgery delays for elderly patients with traumatic spinal cord injury

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Sepsis readmissions have significant impact on health care expenditures in California

Older patients with traumatic spinal cord injury less likely to get surgical treatment compared with younger patients

Researchers awarded grant from British Council to reduce burden of infectious disease in Malaysia

UTHealth School of Public Health working to improve health of Hispanics living along Texas-Mexico border

Mortality rates vary depending on socioeconomic differences among areas in Europe

Dr. Jian-Dong Li receives $1.6 million to develop novel therapeutic targets to treat middle-ear infections

Aridis' Aerucin gets FDA Fast Track Designation for treatment of hospital-acquired and ventilator-associated pneumonia

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Pneumonia News and Research

Latest Pneumonia News and Research

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in